LB Pharmaceuticals Q3 net loss widens to $59.1 million from $3.6 million
LB Pharmaceuticals reported a third-quarter 2026 net loss of $59.1 million, or $1.79 per share, compared with $3.6 million a year earlier, as research and development spending rose to $51.5 million from $2.4 million. The company reported cash, cash equivalents and short-term investments of $403.8 million and said this should fund operations beyond the second quarter of 2029, while it remains on track for topline data from the Phase 3 NOVA-2 trial in the first half of 2027.
Key points
- Net loss was $59.1 million for the quarter ended September 30, 2026, versus $3.6 million a year earlier; net loss per share was $1.79 versus $0.61.
- Research and development expenses were $51.5 million, versus $2.4 million, mainly for the Phase 3 trial of LB-102 in acute schizophrenia and the Phase 2 bipolar depression trial.
- Cash, cash equivalents and short-term investments were $403.8 million as of September 30, 2026, up from $295.2 million at December 31, 2025.
- Topline data from the Phase 3 NOVA-2 trial are expected in the first half of 2027.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.